UniQure triples after brain disorder therapy slows disease progression in trial

** U.S.-listed shares of uniQure QURE, QURE more than triple to a near five-year high of $47.37

** Stock set for its best day ever, if gains hold

** The Netherlands-based drugmaker says its experimental gene therapy significantly slowed progression of a brain disorder in early-to-mid stage study

** QURE is developing a therapy called AMT-130 to treat Huntington's disease, a rare inherited brain disorder that progressively impairs movement, thinking, and behavior, ultimately leading to severe disability and death

** Separately, QURE says it secured a $175 million loan from Hercules Capital HTGC to support the potential U.S. launch of AMT-130

** Including session's move, stock up 162.1% YTD